# (19) World Intellectual Property Organization International Bureau





#### (43) International Publication Date 11 December 2003 (11.12.2003)

**PCT** 

## (10) International Publication Number WO 03/101957 A1

(51) International Patent Classification<sup>7</sup>: C07D 205/04, A61K 31/396

(21) International Application Number: PCT/SE03/00859

(22) International Filing Date: 27 May 2003 (27.05.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 0201661-6

31 May 2002 (31.05.2002) SE

- (71) Applicant (for all designated States except US): AS-TRAZENECA AB [SE/SE]; S-151 85 Södertalje (SE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): AHLQVIST, Matti [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). BOHLIN, Martin [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). INGHARDT, Tord [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). LUNDBLAD, Anita [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). SIGFRIDSSON, Carl-Gustaf [SE/SE]; AstraZeneca R & D Mölndal, s-431 83 Mölndal (SE).
- (74) Agent: ASTRAZENCA AB; Global Intellectual Property, S-151 85 Södertälje (SE).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Declaration under Rule 4.17:


as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

#### Published:

with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NEW SALTS



(e.g. thrombosis) or as anticoagulants.


(57) Abstract: There is provided pharmaceutically-acceptable acid addition salts of compounds of formula (I), wherein R<sup>1</sup> represents C<sub>1-2</sub> alkyl substituted by one or more fluoro substituents; R<sup>2</sup> represents C<sub>1-2</sub> alkyl; and n represents 0, 1 or 2, which salts are useful as prodrugs of competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required

### INTERNATIONAL SEARCH REPORT

Internation application No. PCT/Six 3/00859

A. CLASSIFICATION OF SUBJECT MATTER					
IPC7: C07D 205/04, A61K 31/396 According to International Patent Classification (IPC) or to both n	ational classification and IPC				
B. FIELDS SEARCHED					
Minimum documentation searched (classification system followed b	y classification symbols)				
IPC7: C07D					
Documentation searched other than minimum documentation to th	e extent that such documents are included i	n the fields searched			
SE,DK,FI,NO classes as above					
Electronic data base consulted during the international search (nam	e of data base and, where practicable, searc	h terms used) ·			
C. DOCUMENTS CONSIDERED TO BE RELEVANT		Relevant to claim No.			
Category* Citation of document, with indication, where ap					
A WO 0214270 A1 (ASTRAZENECA AB), (21.02.02)	21 February 2002	1-18			
A WO 0042059 A1 (ASTRAZENECA AB), (20.07.00)	20 July 2000	1-18			
·					
		*			
·					
		,			
		·			
<u> </u>					
Further documents are listed in the continuation of Bo	x C. χ See patent family anne	x.			
* Special categories of cited documents:  "A" document defining the general state of the art which is not considered "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand.					
to be of particular relevance "E" earlier application or patent but published on or after the international filing date	the principle or theory underlying the  "X" document of particular relevance: the  considered novel or cannot be considered.	claimed invention cannot be			
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	step when the document is taken alor "Y" document of particular relevance: the	ne			
"O" document referring to an oral disclosure, use, exhibition or other means	considered to involve an inventive ste combined with one or more other suc	ep when the document is th documents, such combination			
"P" document published prior to the international filing date but later that the priority date claimed	being obvious to a person skilled in t "&" document member of the same paten				
Date of the actual completion of the international search	Date of mailing of the international	search report			
27 August 2003	0 2 -09- 2003				
27 August 2003  Name and mailing address of the ISA/	Authorized officer				
Swedish Patent Office Box 5055, S-102 42 STOCKHOLM	Camer Vanlager /ES				
Facsimile No. +46 8 666 02 86	WOT WIT TO 11				





Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)				
This inte	mational search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:				
1.	Claims Nos.: 19 because they relate to subject matter not required to be searched by this Authority, namely:				
	A method for treatment of the human or animal body by therapy, see rule 39.1				
2.	Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:				
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).				
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)				
1.	As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.				
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.				
3.	As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:				
4.	No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:				
Remark	The additional search fees were accompanied by the applicant's protest.				
	No protest accompanied the payment of additional search fees.				

# INTERNATIONAL ARCH REPORT Information on paramily members

26/07/03 PC

application No.

PCT/SE 03/00859

	nt document n search report		Publication date		Patent family member(s)	Publication date
WO	0214270	A1	21/02/02	AU	8039501 A	25/02/02
***				BR	0113212 A	08/07/03
			•	CA	2415383 A	21/02/02
				EP	1311480 A	21/05/03
				NO	20030675 A	11/02/03
				SE	0002922 D	00/00/00
				US	6433186 B	13/08/02
				US	2002068730 A	06/06/02
				SE	0002921 D	00/00/00
WO	0042059	A1	20/07/00	AU	2336200 A	01/08/00
	•••••	•	,,	BR	0007453 A	30/10/01
				CA	2355792 A	20/07/00
				CN	1343217 T	03/04/02
				CZ	20012529 A	14/11/01
				DE	69906692 D	00/00/00
				EE	200100371 A	15/02/02
				EP	1049438 A,B	08/11/00
				SE	1049438 T3	
				EP	1150996 A	07/11/01
				IL	143987 D	00/00/00
				JP	2002500927 T	15/01/02
				JP	2002535250 T	22/10/02
				NO	20013319 A	12/09/01
				PL	349769 A	09/09/02
				SE	9900071 D	00/00/00
				TR	200102037 T	00/00/00
				US	6582543 B	24/06/03
				SE	9904228 D	00/00/00